Physician profile
James P Hamilton
NPI 1295802791
$11,213.57
in general payments reported to CMS, 2019-2025
21 companies · $4,354 in 2025
The $4,354 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $80.36 · 2021: $2,425 · 2022: $562 · 2023: $2,176 · 2024: $1,135 · 2025: $4,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,361 · Honoraria: $2,400 · Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,361.00 |
| Honoraria | $2,400.00 |
| Food and Beverage | $1,903.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,150.00 | 2019-2025 | |
| Orphalan INC | $2,582.96 | 2023-2025 | Cuvrior |
| Theratechnologies INC. | $2,000.00 | 2021 | |
| Albireo Pharma, INC. | $1,436.00 | 2023 | Bylvay |
| Madrigal Pharmaceuticals | $751.84 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.96 | 2023-2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $173.73 | 2024-2025 | Iqirvo, Bylvay |
| Boston Scientific Corporation | $170.30 | 2019-2020 | |
| Gilead Sciences, INC. | $160.10 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $136.82 | 2022-2025 | Terlivaz |
| Janssen Biotech, INC. | $115.31 | 2024 | Tremfya |
| Medtronic, INC. | $110.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.94 | 2023-2025 | Livtencity, Eohilia |
| Daiichi Sankyo INC. | $27.20 | 2024 | Injectafer |
| Intercept Pharmaceuticals, INC. | $24.91 | 2023 | Ocaliva |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20.69 | 2025 | Wegovy |
| Amgen INC. | $19.91 | 2025 | Uplizna |
| Cook Medical LLC | $16.54 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.